<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Unconjugated hyperbilirubinemia in term and late preterm newborns: Screening
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Unconjugated hyperbilirubinemia in term and late preterm newborns: Screening
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Unconjugated hyperbilirubinemia in term and late preterm newborns: Screening
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Ronald J Wong, BA
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Vinod K Bhutani, MD, FAAP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Steven A Abrams, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Carrie Armsby, MD, MPH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            May 01, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nearly all newborn infants develop elevated bilirubin levels (ie, total serum or plasma bilirubin [TSB] &gt;1 mg/dL [17 micromol/L], which is the upper limit of normal for adults). As TSB levels increase, the newborn may develop visible jaundice. Newborns with severe hyperbilirubinemia (defined as TSB &gt;25 mg/dL [428 micromol/L] in newborns ≥35 weeks gestation) are at risk for developing neurologic sequelae of bilirubin toxicity. It is important to identify newborns at risk for severe hyperbilirubinemia and to provide timely and appropriate preventive therapy, if warranted.
        </p>
        <p>
         This topic will discuss screening for unconjugated hyperbilirubinemia in newborns ≥35 weeks of gestation, including the approach to identifying newborns at risk for progressive and/or severe hyperbilirubinemia. Other related issues are discussed separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pathogenesis and etiology of neonatal hyperbilirubinemia (see
         <a class="medical medical_review" href="/z/d/html/5020.html" rel="external">
          "Unconjugated hyperbilirubinemia in neonates: Etiology and pathogenesis"
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Risk factors, clinical manifestations, and neurologic complications of neonatal hyperbilirubinemia (see
         <a class="medical medical_review" href="/z/d/html/4994.html" rel="external">
          "Unconjugated hyperbilirubinemia in neonates: Risk factors, clinical manifestations, and neurologic complications"
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Management of neonatal hyperbilirubinemia (see
         <a class="medical medical_review" href="/z/d/html/5063.html" rel="external">
          "Unconjugated hyperbilirubinemia in term and late preterm newborns: Initial management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/121592.html" rel="external">
          "Unconjugated hyperbilirubinemia in term and late preterm newborns: Escalation of care"
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hyperbilirubinemia in preterm infants (gestational age [GA] &lt;35 weeks) (see
         <a class="medical medical_review" href="/z/d/html/5037.html" rel="external">
          "Unconjugated hyperbilirubinemia in preterm infants &lt;35 weeks gestation"
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Conjugated (direct) hyperbilirubinemia in neonates (see
         <a class="medical medical_review" href="/z/d/html/5945.html" rel="external">
          "Causes of cholestasis in neonates and young infants"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H56431491">
         <span class="h1">
          DEFINITIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following terms are used throughout this topic:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Benign neonatal hyperbilirubinemia
         </strong>
         is a transient and normal increase in bilirubin levels occurring in nearly all newborn infants. It was previously referred to as "physiologic jaundice."
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Severity of hyperbilirubinemia
         </strong>
         – Various definitions have been used to define "severe" versus "extreme" or "hazardous" neonatal hyperbilirubinemia. Throughout this topic review, we use the following total serum or plasma bilirubin (TSB) levels to define these terms:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Severe neonatal hyperbilirubinemia
         </strong>
         is defined as TSB &gt;25 mg/dL (428 micromol/L).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Extreme or hazardous neonatal hyperbilirubinemia
         </strong>
         is defined as TSB ≥30 mg/dL (513 micromol/L).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bilirubin-induced neurologic disorders (BIND)
         </strong>
         refer to the spectrum of neurotoxic injury resulting from free (or unbound) bilirubin crossing the blood-brain barrier and binding to brain tissue. BIND includes acute and chronic bilirubin encephalopathy (ABE and CBE, respectively) as well as more subtle neurologic dysfunction. The manifestations of BIND, including ABE and CBE, are described separately. (See
         <a class="medical medical_review" href="/z/d/html/4994.html" rel="external">
          "Unconjugated hyperbilirubinemia in neonates: Risk factors, clinical manifestations, and neurologic complications", section on 'Consequences of severe hyperbilirubinemia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Assessment of neonatal hyperbilirubinemia is based upon total bilirubin rather than unconjugated bilirubin levels alone because neonatal hyperbilirubinemia is mostly due to increased bilirubin production, resulting primarily in unconjugated bilirubin that can be exacerbated by conditions causing impaired bilirubin elimination. Cholestasis, which presents with primarily elevated conjugated (direct) bilirubin, is a rare cause of neonatal hyperbilirubinemia. (See
         <a class="medical medical_review" href="/z/d/html/5020.html" rel="external">
          "Unconjugated hyperbilirubinemia in neonates: Etiology and pathogenesis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5945.html" rel="external">
          "Causes of cholestasis in neonates and young infants"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3255848051">
         <span class="h1">
          BENEFITS OF SCREENING
         </span>
         <span class="headingEndMark">
          —
         </span>
         We agree with the guidelines of the American Academy of Pediatrics (AAP) and the Canadian Paediatric Society (CPS), which recommend universal bilirubin screening before discharge in all term and late term newborns to identify newborns at risk for developing severe hyperbilirubinemia [
         <a href="#rid1">
          1,2
         </a>
         ]. Links to these and other society guidelines are provided separately. (See
         <a class="local">
          'Society guideline links'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3067366740">
         <span class="h2">
          Rationale for screening
         </span>
         <span class="headingEndMark">
          —
         </span>
         The rationale for screening all newborns for hyperbilirubinemia during the birth hospitalization is based upon the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hyperbilirubinemia is common in newborns, with nearly all neonates having total serum or plasma bilirubin (TSB) levels above the upper limit of normal for older children and adults. TSB levels &gt;25 mg/dL [428 micromol/L]) are far less common. However, before bilirubin screening was a routine part of newborn care, approximately 1 in 600 newborns developed a TSB &gt;25 mg/dL [428 µmol/L]. The incidence has declined considerably with routine screening, presumably due to identifying and treating at-risk newborns  (
         <a class="graphic graphic_figure graphicRef101082" href="/z/d/graphic/101082.html" rel="external">
          figure 1
         </a>
         ). Additional details regarding the epidemiology of neonatal hyperbilirubinemia, including incidence and trends over time, are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/4994.html" rel="external">
          "Unconjugated hyperbilirubinemia in neonates: Risk factors, clinical manifestations, and neurologic complications", section on 'Epidemiology'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If severe hyperbilirubinemia is not detected and treated in a timely manner, bilirubin may progress to extreme levels (TSB ≥30 mg/dL [513 micromol/L]), and consequences can be dire (ie, severe permanent neurologic injury). (See
         <a class="medical medical_review" href="/z/d/html/4994.html" rel="external">
          "Unconjugated hyperbilirubinemia in neonates: Risk factors, clinical manifestations, and neurologic complications", section on 'Consequences of severe hyperbilirubinemia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Universal screening aims to identify newborns who are at risk for developing progressive and/or severe hyperbilirubinemia so that treatment can be initiated before the newborn develops adverse consequences. (See
         <a class="local">
          'Approach to screening'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/5063.html" rel="external">
          "Unconjugated hyperbilirubinemia in term and late preterm newborns: Initial management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1591124034">
         <span class="h2">
          Supporting evidence
         </span>
         <span class="headingEndMark">
          —
         </span>
         Evidence supporting universal newborn bilirubin screening comes from observational studies demonstrating that routine screening before discharge reduces the risk of developing severe hyperbilirubinemia (ie, TSB levels &gt;25 mg/dL [428 micromol/L])  (
         <a class="graphic graphic_figure graphicRef101082" href="/z/d/graphic/101082.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid3">
          3-7
         </a>
         ]. Universal screening also appears to reduce hospital readmissions for neonatal hyperbilirubinemia [
         <a href="#rid8">
          8,9
         </a>
         ].
        </p>
        <p>
         Direct evidence is lacking to conclusively show that screening reduces the adverse consequences of hyperbilirubinemia (bilirubin-induced neurologic disorders [BIND]). However, indirect data suggest a strong link between severe hyperbilirubinemia and BIND [
         <a href="#rid10">
          10-12
         </a>
         ]. Thus, it is reasonable to expect that reducing the incidence of severe hyperbilirubinemia will reduce the incidence of BIND.
        </p>
        <p>
         In a clinical trial from South Africa involving 1858 healthy newborns ≥35 weeks gestation who were randomly assigned to predischarge transcutaneous bilirubin screening or standard care (visual inspection for jaundice only), screening reduced the readmission rate for neonatal hyperbilirubinemia (1.4 versus 5.6 percent; relative risk [RR] 0.25, 95% CI 0.14-0.46) and reduced the incidence of severe hyperbilirubinemia (0.3 versus 1.2 percent; RR 0.27, 95% CI 0.08-0.97) [
         <a href="#rid9">
          9
         </a>
         ]. Use of phototherapy during the birth hospitalization was higher in the screening group (5.2 versus 1.9 percent). Only two newborns in the trial required exchange transfusion (both in the standard care group). One newborn in the standard care group developed clinical evidence of BIND.
        </p>
        <p>
         Observational studies comparing universal screening with a selective testing strategy (ie, testing based upon the extent of visible jaundice and/or risk factors for hyperbilirubinemia) have generally reported that universal screening is more effective in reducing severe hyperbilirubinemia. In a large retrospective study of newborns ≥35 weeks gestation, the incidence of hyperbilirubinemia exceeding the AAP-recommended threshold for exchange transfusion was lower in birth facilities that had implemented universal screening compared with facilities using a selective testing strategy (0.17 versus 0.45 percent) [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
         In another large multicenter study, the incidence of severe hyperbilirubinemia decreased after the implementation of universal screening compared with pre-implementation historical controls (0.02 versus 0.07 percent) [
         <a href="#rid8">
          8
         </a>
         ]. In addition, the rate of hospital readmissions for neonatal hyperbilirubinemia decreased after implementation of universal screening.
        </p>
        <p class="headingAnchor" id="H1711453650">
         <span class="h1">
          HARMS OF SCREENING
         </span>
         <span class="headingEndMark">
          —
         </span>
         The benefits of screening must be weighed against the potential downsides, which include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Additional blood draws – Some newborns may require additional laboratory testing and blood draws, which can cause pain and discomfort to the newborn and may or may not ultimately lead to specific intervention or other benefit to the patient.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Falsely concerning results (false positives) – For newborns screened using transcutaneous bilirubin (TcB) devices, there is a risk that the TcB value may overestimate the true total serum or plasma bilirubin (TSB) level. This may result in additional validation testing and, in some cases, potentially unnecessary treatment. This is a particular concern in newborns with darkly pigmented skin, for whom TcB can overestimate TSB, as discussed below. (See
         <a class="local">
          'Transcutaneous bilirubin (TcB)'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Falsely reassuring results (false negatives) – TcB measurements can also underestimate TSB levels, which may lead to delays in appropriate treatment for hyperbilirubinemia. Even when TcB results are accurate, reassuring screening results (bilirubin level well below the threshold for treatment) may falsely reassure parents/caregivers and healthcare providers that the newborn is not at risk of subsequently developing clinically significant hyperbilirubinemia. The parents/caregivers may be less likely to seek care if the newborn becomes jaundiced and healthcare providers may be less likely to recheck bilirubin levels since the initial value was normal. This is a particular concern in newborns who undergo bilirubin screening and are discharged from the birth hospitalization early after birth (within the first 24 to 48 hours) and those with glucose-6-phosphate dehydrogenase (G6PD) deficiency, for whom neonatal hyperbilirubinemia can be prolonged. For all newborns, it is imperative to ensure timely follow-up and to provide clear discharge instructions about when to seek care. (See
         <a class="local">
          'Determining follow-up and need for additional evaluation and/or treatment'
         </a>
         below and
         <a class="local">
          'Outpatient follow-up'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Unnecessary treatments – In theory, it is possible that some newborns with TSB levels above the treatment threshold could have spontaneous resolution of the hyperbilirubinemia during the first week after birth without intervention and without ever reaching a dangerous level. While the trajectory of hyperbilirubinemia can be predicted to some extent based upon risk factors (eg, lower gestational age [GA], hemolysis), these predictions are imperfect. Nevertheless, the treatment thresholds established by the American Academy of Pediatrics (AAP) are intended to reflect the point at which the benefits of phototherapy likely exceed its potential harms, taking into account the hour-specific TSB level, GA, and risk of bilirubin neurotoxicity [
         <a href="#rid1">
          1
         </a>
         ]. These thresholds are based largely on expert opinion rather than high-certainty evidence. The potential harms of phototherapy are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5063.html" rel="external">
          "Unconjugated hyperbilirubinemia in term and late preterm newborns: Initial management", section on 'Adverse effects'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Parent/caregiver anxiety and interference with establishing breastfeeding – Parents/caregivers may experience increased worry and anxiety if their newborn requires additional blood testing. In addition, treatment may interfere with establishing breastfeeding.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increased costs – The costs associated with newborn bilirubin screening are generally low, but may be a limitation in resource-constrained settings. Cost-effectiveness studies performed in the current era suggest that while the approach of universal screening increases costs during the birth hospitalization and post-discharge follow-up visits, these costs are partially offset by reduced costs from fewer emergency room visits, hospital readmissions, and long-term care associated with potential complications of hyperbilirubinemia (ie, chronic bilirubin encephalopathy [CBE, previously called kernicterus]) [
         <a href="#rid13">
          13,14
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2479177107">
         <span class="h1">
          APPROACH TO SCREENING
         </span>
         <span class="headingEndMark">
          —
         </span>
         The approach to identifying and treating newborns at risk for severe hyperbilirubinemia should be systematic [
         <a href="#rid1">
          1
         </a>
         ]. We suggest performing bilirubin screening in all newborns prior to discharge. Screening can be performed using either a transcutaneous bilirubin (TcB) device or a laboratory total serum or plasma bilirubin (TSB) measurement. The bilirubin level is used in conjunction with assessment of the risk for development of severe hyperbilirubinemia to determine the need for further evaluation and treatment. (See
         <a class="local">
          'Interpretation of bilirubin testing'
         </a>
         below and
         <a class="local">
          'Determining follow-up and need for additional evaluation and/or treatment'
         </a>
         below.)
        </p>
        <p>
         Newborn bilirubin screening involves the following steps, each of which is described in greater detail in the sections below:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Perform TSB or TcB measurements at 24 to 48 hours after birth or before discharge, whichever is sooner. Newborns with visible jaundice in the first 24 hours after birth or certain other risk factors for early severe hyperbilirubinemia must be tested sooner. (See
         <a class="local">
          'Bilirubin testing methods'
         </a>
         below and
         <a class="local">
          'Timing of screening'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Determine the hour-specific TSB threshold for phototherapy based upon the newborn's gestational age (GA), postnatal age, and risk factors for neurotoxicity  (
         <a class="graphic graphic_figure graphicRef56490 graphicRef139427" href="/z/d/graphic/56490.html" rel="external">
          figure 2A-B
         </a>
         )(
         <a class="calc calc_professional" href="/z/d/html/13421.html" rel="external">
          calculator 1
         </a>
         ). (See
         <a class="local">
          'Risk assessment'
         </a>
         below and
         <a class="local">
          'Interpretation of bilirubin testing'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If screening was performed with a TcB measurement and the value is &gt;15 mg/dL (257 micromol/L) or is within 3 mg/dL (51 micromol/L) of the phototherapy threshold, confirm with a TSB measurement. The decision to begin phototherapy is based upon the TSB value. (See
         <a class="local">
          'Transcutaneous bilirubin (TcB)'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If the newborn's TSB is at or above the phototherapy threshold, begin treatment, as discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5063.html" rel="external">
          "Unconjugated hyperbilirubinemia in term and late preterm newborns: Initial management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If the newborn's bilirubin level is below the phototherapy threshold, calculate the difference between the hour-specific TSB phototherapy threshold and newborn's bilirubin level. Decisions regarding timing and need for follow-up testing are based upon this difference  (
         <a class="graphic graphic_table graphicRef139498" href="/z/d/graphic/139498.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Interpretation of bilirubin testing'
         </a>
         below and
         <a class="local">
          'Determining follow-up and need for additional evaluation and/or treatment'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1270660602">
         <span class="h2">
          Bilirubin testing methods
         </span>
        </p>
        <p class="headingAnchor" id="H3023504957">
         <span class="h3">
          Advantages and disadvantages of the tests
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bilirubin screening can be performed noninvasively with a TcB device or with a laboratory measurement of TSB, which requires a blood draw. In our center, we use TSB; other centers predominantly rely on TcB for screening.
        </p>
        <p>
         A TSB measurement is the gold standard for assessing neonatal bilirubin levels and its main advantage is that it is more accurate, particularly at high bilirubin levels. In addition, it is not impacted by skin pigmentation. Its main disadvantage is that it requires a blood draw. However, if the TSB is obtained at the time of routine metabolic screening, no additional blood draw is necessary. (See
         <a class="local">
          'Total serum or plasma bilirubin (TSB)'
         </a>
         below.)
        </p>
        <p>
         The advantages of using a TcB device are that it does not require a blood draw, it reduces laboratory costs, and serial measurements can be used to monitor the TSB trajectory. Although TcB does not directly measure the serum bilirubin, TcB measurements are valid estimates of TSB levels and can be used as a screening tool to identify newborns who should have a TSB level measured [
         <a href="#rid7">
          7
         </a>
         ]. (See
         <a class="local">
          'Transcutaneous bilirubin (TcB)'
         </a>
         below.)
        </p>
        <p>
         TcB and TSB should
         <strong>
          not
         </strong>
         be used interchangeably. If therapeutic interventions are being considered, a TcB measurement must be confirmed with a TSB measurement [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="local">
          'When to confirm with TSB'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3710672110">
         <span class="h3">
          Total serum or plasma bilirubin (TSB)
         </span>
         <span class="headingEndMark">
          —
         </span>
         TSB can be measured in the laboratory or with a point-of-care analyzer. Both methods can be performed on small-volume blood samples (≤0.3 mL), which are obtainable via a heel-stick.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical laboratory testing
         </strong>
         – Analyzers used in core clinical laboratories directly measure TSB via a chemical reaction (diazo method) or spectrophotometrically. These methods are the gold standard for TSB measurement [
         <a href="#rid1">
          1,3
         </a>
         ]. The hour-specific nomograms used in the 2022 American Academy of Pediatrics (AAP) guidelines are based upon TSB measurements performed by chemical laboratory analyzers utilizing the diazo method.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Interlaboratory and inter-instrument variabilities in TSB measurements have been reported [
         <a href="#rid15">
          15,16
         </a>
         ]. The variability for TSB measurements within a given laboratory is usually &lt;6 percent [
         <a href="#rid17">
          17
         </a>
         ]. It is important that laboratories perform routine quality assurance and proficiency testing, as changes, including recalibration of bilirubin assays, can result in clinically significant measurement error. This was illustrated by a study demonstrating the effects of a recalibration of a commercially-available assay that resulted in reductions in the need for phototherapy during birth hospitalizations and fewer readmissions for phototherapy [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Point-of-care testing
         </strong>
         – Point-of-care (POC) analyzers measure TSB spectrophotometrically and require minimal blood volumes (eg, capillary sample by heelstick). Some of these devices can simultaneously perform other tests (eg, blood gas analysis, blood electrolyte levels) on a single sample.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         TSB measurements on these devices generally correlate well with standard laboratory analyzers, but they are less accurate at high TSB levels. In a meta-analysis of ten observational studies, POC devices slightly underestimated TSB compared with clinical laboratory measurements (average difference 0.8 mg/dL [14 micromol/L]) [
         <a href="#rid19">
          19
         </a>
         ]. At TSB levels &gt;14.6 mg/dL (250 micromol/L), these differences may be more substantial, and the values should be confirmed with standard core laboratory methods [
         <a href="#rid20">
          20,21
         </a>
         ]. However, if the point-of-care TSB level is markedly elevated, phototherapy should be initiated while awaiting confirmatory results from the laboratory.
        </p>
        <p>
        </p>
        <p>
         Additional details of bilirubin measurement are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/3573.html" rel="external">
          "Overview of liver biochemical tests", section on 'Measurement of serum bilirubin'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3690627595">
         <span class="h3">
          Transcutaneous bilirubin (TcB)
         </span>
         <span class="headingEndMark">
          —
         </span>
         TcB measurement is performed using a hand-held device that emits light at different wavelengths and measures the difference in optical densities of light reflected back from the skin [
         <a href="#rid1">
          1,22
         </a>
         ]. Although TcB measurements do not directly measure TSB, they are valid and reliable when used to screen and identify newborns who require further evaluation.
        </p>
        <p class="headingAnchor" id="H470641502">
         <span class="h4">
          Technique
         </span>
         <span class="headingEndMark">
          —
         </span>
         TcB devices should be used in accordance with each specific manufacturer's instructions. Generally, the forehead is the most convenient site for testing. Exposure to sunlight can impact TcB device accuracy. Therefore, in outpatient settings, when a newborn has had prior exposure to sunlight, the sternum is the preferred site since it usually has been covered. TcB measurements may vary if performed on different sites on the same newborn (eg, measurements on the upper body may be higher than on the lower body, reflecting the cephalocaudal progression of jaundice).
        </p>
        <p class="headingAnchor" id="H3208969752">
         <span class="h4">
          Advantages
         </span>
         <span class="headingEndMark">
          —
         </span>
         The advantages of using TcB for screening are that it can be performed quickly, results are available immediately, it does not require a blood draw, and it may be less costly compared with TSB measurements [
         <a href="#rid4">
          4,7,13,23-25
         </a>
         ].
        </p>
        <p>
         The use of TcB for screening reduces the number of blood tests for bilirubin measurement without compromising detection of at-risk newborns [
         <a href="#rid7">
          7,13,26,27
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3826687195">
         <span class="h4">
          Accuracy
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is generally a good correlation between TcB and TSB (typically within 2 to 3 mg/dL [34 to 51 micromol/L]) when the TSB level is &lt;15 mg/dL (257 micromol/L) [
         <a href="#rid23">
          23,28-31
         </a>
         ]. At TSB levels ≥15 mg/dL (257 micromol/L), TcB can substantially under- or overestimate TSB. For TSB levels &gt;20 mg/dL (342 micromol/L), some TcB devices will display "error" instead of a bilirubin value.
        </p>
        <p>
         The magnitude and direction of the difference between TcB and TSB varies, depending on [
         <a href="#rid1">
          1
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Device used
         </strong>
         – There can be significant variability between different TcB devices, even when using the same manufacturer [
         <a href="#rid30">
          30,32
         </a>
         ]. Thus, it is important that for an individual newborn, the same device is used to measure TcB levels over the course of an individual newborn's hospital stay [
         <a href="#rid33">
          33
         </a>
         ]. This can be challenging if different TcB devices are used in the same care unit. In addition, when a new device is initially put into routine clinical use, its measurements should be compared with TSB levels performed in the laboratory to ensure good correlation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Skin pigmentation
         </strong>
         – Skin pigmentation affects light reflectance which can potentially impact the accuracy of TcB readings. Different methodologies have been developed by TcB device manufacturers to minimize this effect. However, these methods are not perfect.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         TcB generally overestimates TSB in newborns with darker skin pigmentation and underestimates TSB in newborns with lighter pigmented skin [
         <a href="#rid23">
          23,24,30,34-36
         </a>
         ]. In a study that evaluated 925 paired TcB and TSB measurements in healthy newborns, the mean difference between the two values among African-American newborns was 1.51 mg/dL (26 micromol/L) compared with 0.84 (14 micromol/L) for the entire cohort [
         <a href="#rid30">
          30
         </a>
         ]. A similar study that compared &gt;2000 pairs of TcB and TSB measurements in Black African newborns found that TcB overestimated TSB by ≥3 mg/dL (51 micromol/L) in 43 percent of newborns [
         <a href="#rid36">
          36
         </a>
         ]. These findings suggest that TcB values should be interpreted with caution in newborns with darker skin pigmentation. Nevertheless, TcB screening performs better than visual assessment alone [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Exposure to sunlight or phototherapy
         </strong>
         – TcB accuracy is reduced with prior exposure to sunlight or phototherapy [
         <a href="#rid37">
          37,38
         </a>
         ]. Some manufacturers have suggested covering an area of skin with a patch to protect it from exposure to sunlight if the newborn is in a sunny room. However, it is unclear if this is an effective strategy to mitigate this issue. TcB should
         <strong>
          not
         </strong>
         be used in newborns receiving phototherapy. (See
         <a class="medical medical_review" href="/z/d/html/5063.html" rel="external">
          "Unconjugated hyperbilirubinemia in term and late preterm newborns: Initial management", section on 'Monitoring during phototherapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         A systematic review identified 54 studies assessing the accuracy of TcB using various devices compared with TSB measurements [
         <a href="#rid31">
          31
         </a>
         ]. TcB cut-off values and thresholds to define hyperbilirubinemia varied considerably in the different studies. The reported sensitivity of TcB for predicting TSB ranged from 68 to 100 percent and specificity ranged from 21 to 88 percent.
        </p>
        <p class="headingAnchor" id="H3347880758">
         <span class="h4">
          Nomograms in different populations
         </span>
         <span class="headingEndMark">
          —
         </span>
         For most of the commercially available TcB devices, nomograms have been developed that define the range of normal values and the
         <sup>
         </sup>
         75
         <sup>
          th
         </sup>
         and 95
         <sup>
          th
         </sup>
         percentiles according to postnatal age [
         <a href="#rid25">
          25,39-42
         </a>
         ]. Many of the available studies were performed in populations that included predominantly breastfed White newborns. However, there are available data across different racial and ethnic groups and regions of the world [
         <a href="#rid25">
          25,39-51
         </a>
         ]. Systematic reviews of these studies have found that TcB nomograms vary across different populations, though all demonstrate an hourly progression to peak levels at ages three to five days and a transient plateau that is subsequently followed by decline [
         <a href="#rid43">
          43,52
         </a>
         ]. Possible explanations for the variability among different studies include variability in skin pigmentation, differences in breastfeeding practices, genetic factors (eg, prevalence of glucose-6-phosphate dehydrogenase [G6PD] deficiency or Gilbert syndrome in the study population), and differences in study design (eg, enrollment criteria, TcB device used).
        </p>
        <p class="headingAnchor" id="H3444558548">
         <span class="h4">
          When to confirm with TSB
         </span>
         <span class="headingEndMark">
          —
         </span>
         TcB measurements should be confirmed with TSB measurements in the following situations [
         <a href="#rid1">
          1,20,51,53-55
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         When therapeutic interventions are being considered (phototherapy or exchange transfusion); however, phototherapy can be initiated while awaiting confirmatory TSB results.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If TcB is within 3 mg/dL (51 micromol/L) of the phototherapy threshold  (
         <a class="graphic graphic_figure graphicRef56490 graphicRef139427" href="/z/d/graphic/56490.html" rel="external">
          figure 2A-B
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If TcB is &gt;15 mg/dL (257 micromol/L).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If the TcB device displays an "error" message or if there is any question regarding the validity of the TcB measurement.
        </p>
        <p>
        </p>
        <p>
         TcB measurements are
         <strong>
          not
         </strong>
         reliable in newborns undergoing phototherapy and should not be used in this setting [
         <a href="#rid1">
          1,56,57
         </a>
         ]. Management decisions regarding phototherapy should be guided by TSB values. (See
         <a class="medical medical_review" href="/z/d/html/5063.html" rel="external">
          "Unconjugated hyperbilirubinemia in term and late preterm newborns: Initial management", section on 'Initial intervention (phototherapy)'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1925529962">
         <span class="h3">
          Other methods
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Color comparison charts and plastic ictometers
         </strong>
         – In resource-limited settings, color comparison charts or rulers (ictometers) are a low-cost alternative to TcB [
         <a href="#rid58">
          58,59
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Smart phone applications
         </strong>
         – There are a growing number of direct-to-consumer applications that have been developed for smart phones and other devices to assess newborn jaundice [
         <a href="#rid60">
          60-62
         </a>
         ]. Most of these applications assess how yellow the newborn’s sclerae or skin are using the smart phone’s digital camera. Further validation of these devices is needed before they can be recommended for routine use.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3186536133">
         <span class="h2">
          Timing of screening
         </span>
         <span class="headingEndMark">
          —
         </span>
         The timing of the first bilirubin test depends upon whether the newborn has risk factors for developing early severe hyperbilirubinemia. (See
         <a class="local">
          'Risk assessment'
         </a>
         below.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Indications for early screening
         </strong>
         – Newborns with any of the following warrant early testing [
         <a href="#rid1">
          1
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Newborns with positive direct antiglobulin test (DAT). TSB should be measured as part of the evaluation for alloimmune hemolytic disease, as discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5933.html" rel="external">
          "Alloimmune hemolytic disease of the newborn: Postnatal diagnosis and management", section on 'Evaluation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Newborns with onset of visible jaundice within the first 24 hours after birth. This finding suggests an underlying hemolytic process. TSB measurement is appropriate in this setting.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Newborns who have a first-degree relative with a heritable hemolytic disease (eg, glucose-6 phosphate dehydrogenase [G6PD] deficiency or hereditary spherocytosis).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Routine screening
         </strong>
         – For all other newborns, TSB or TcB levels should be checked at 24 to 48 hours after birth or before discharge, whichever is sooner [
         <a href="#rid1">
          1
         </a>
         ]. In our center, we obtain TSB levels in all newborns at the time of the newborn metabolic screen. (See
         <a class="medical medical_review" href="/z/d/html/4980.html" rel="external">
          "Overview of newborn screening", section on 'Timing of testing'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H187041405">
         <span class="h2">
          Clinical assessment
         </span>
         <span class="headingEndMark">
          —
         </span>
         In addition to performing bilirubin testing, the clinician should clinically assess the newborn for risk factors for hyperbilirubinemia and visible jaundice.
        </p>
        <p class="headingAnchor" id="H1551968582">
         <span class="h3">
          Risk assessment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Newborns should be assessed for risk of developing progressive and/or severe hyperbilirubinemia and risk of developing bilirubin neurotoxicity. The newborn's predischarge TSB or TcB level is the strongest predictor of subsequent severe hyperbilirubinemia. Other risk factors are summarized in the tables  (
         <a class="graphic graphic_table graphicRef139425" href="/z/d/graphic/139425.html" rel="external">
          table 2
         </a>
         and
         <a class="graphic graphic_table graphicRef64584" href="/z/d/graphic/64584.html" rel="external">
          table 3
         </a>
         ) and are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/4994.html" rel="external">
          "Unconjugated hyperbilirubinemia in neonates: Risk factors, clinical manifestations, and neurologic complications", section on 'Risk factors'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1537939509">
         <span class="h3">
          Physical examination
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Visual assessment for jaundice
         </strong>
         – All newborn infants should be routinely assessed during their birth hospitalization for the onset and progression of jaundice. Visual jaundice assessment should occur when vital signs are taken or at least every 12 hours as part of routine newborn management [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5068.html" rel="external">
          "Overview of the routine management of the healthy newborn infant"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Newborns who develop jaundice within the first 24 hours of birth should undergo early TSB testing, as discussed above. (See
         <a class="local">
          'Timing of screening'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         While visual assessment for jaundice remains an important part of the approach to assessing risk of severe hyperbilirubinemia and assessing progression, clinicians should recognize that visual assessment of jaundice is not a reliable way to estimate the degree of hyperbilirubinemia, as discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4994.html" rel="external">
          "Unconjugated hyperbilirubinemia in neonates: Risk factors, clinical manifestations, and neurologic complications", section on 'Jaundice'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other concerning physical findings
         </strong>
         :
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Significant bruising (see
         <a class="medical medical_review" href="/z/d/html/5031.html" rel="external">
          "Neonatal birth injuries", section on 'Bruising and petechiae'
         </a>
         )
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Cephalohematoma (see
         <a class="medical medical_review" href="/z/d/html/5031.html" rel="external">
          "Neonatal birth injuries"
         </a>
         )
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Findings concerning for Down syndrome (see
         <a class="medical medical_review" href="/z/d/html/2917.html" rel="external">
          "Down syndrome: Clinical features and diagnosis", section on 'Dysmorphic features'
         </a>
         )
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Macrosomia (eg, in a newborn of a diabetic mother) (see
         <a class="medical medical_review" href="/z/d/html/5058.html" rel="external">
          "Infants of mothers with diabetes (IMD)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3903006807">
         <span class="h3">
          Feeding assessment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Exclusively breastfed newborns are at greater risk for developing hyperbilirubinemia due to suboptimal intake [
         <a href="#rid1">
          1
         </a>
         ]. A feeding assessment, including frequency and quality of breastfeeding, and assessment of urine and stool output, should reviewed for every newborn. (See
         <a class="medical medical_review" href="/z/d/html/4986.html" rel="external">
          "Initiation of breastfeeding", section on 'Assessment of intake'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H697049433">
         <span class="h3">
          Family history
         </span>
         <span class="headingEndMark">
          —
         </span>
         The family history and ancestry should be reviewed with particular attention to inherited hemolytic disorders such as G6PD deficiency. Clinicians should ask if the newborn's siblings or parents required treatment for jaundice in infancy. However, in many affected individuals, the family history is negative. Thus, inquiring about newborn's ancestry can inform risk. The prevalence of glucose-6-phosphate dehydrogenase (G6PD) deficiency varies by region and ethnicity, with higher prevalence among Kurdish Jews; Black individuals from sub-Saharan Africa or Brazil; African-Americans; and people from Thailand, South China, and India  (
         <a class="graphic graphic_figure graphicRef129472" href="/z/d/graphic/129472.html" rel="external">
          figure 3
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/7111.html" rel="external">
          "Diagnosis and management of glucose-6-phosphate dehydrogenase (G6PD) deficiency"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H843509175">
         <span class="h1">
          INTERPRETATION OF BILIRUBIN TESTING
         </span>
        </p>
        <p class="headingAnchor" id="H3117925368">
         <span class="h2">
          Approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bilirubin values are interpreted relative to the hour-specific thresholds for treatment, which vary depending upon the newborn's gestational age (GA) and other risk factors for neurotoxicity  (
         <a class="graphic graphic_table graphicRef139425" href="/z/d/graphic/139425.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid1">
          1
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/5063.html" rel="external">
          "Unconjugated hyperbilirubinemia in term and late preterm newborns: Initial management"
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Phototherapy thresholds
         </strong>
         – Total serum or plasma bilirubin (TSB) thresholds for initiating phototherapy are summarized in the figures:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In newborns
         <strong>
          without
         </strong>
         risk factors for neurotoxicity (other than GA)  (
         <a class="graphic graphic_figure graphicRef56490" href="/z/d/graphic/56490.html" rel="external">
          figure 2A
         </a>
         )
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In newborns
         <strong>
          with
         </strong>
         at least one risk factor for neurotoxicity (other than GA)  (
         <a class="graphic graphic_figure graphicRef139427" href="/z/d/graphic/139427.html" rel="external">
          figure 2B
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Exchange transfusion thresholds
         </strong>
         – Thresholds for exchange transfusion are summarized in the figures:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In newborns without risk factors for neurotoxicity  (
         <a class="graphic graphic_figure graphicRef68219" href="/z/d/graphic/68219.html" rel="external">
          figure 4A
         </a>
         )
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In newborns with risk factors for neurotoxicity  (
         <a class="graphic graphic_figure graphicRef139429" href="/z/d/graphic/139429.html" rel="external">
          figure 4B
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         The predischarge bilirubin level can be used to guide subsequent management using the following steps:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Step 1 – Use the appropriate hour-specific nomogram to determine the hour-specific TSB threshold for phototherapy:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For newborns
         <strong>
          without
         </strong>
         risk factors for neurotoxicity (other than GA)  (
         <a class="graphic graphic_figure graphicRef56490" href="/z/d/graphic/56490.html" rel="external">
          figure 2A
         </a>
         )
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For newborns
         <strong>
          with
         </strong>
         one or more risk factor for neurotoxicity (other than GA)  (
         <a class="graphic graphic_figure graphicRef139427" href="/z/d/graphic/139427.html" rel="external">
          figure 2B
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Step 2 – If the newborn's predischarge bilirubin level is at or above the treatment threshold, begin treatment urgently. Note that if screening is performed with transcutaneous bilirubin (TcB) and the value is &gt;15 mg/dL (257 micromol/L) or is within 3 mg/dL (51 micromol/L) of the treatment threshold, it should be confirmed with a TSB measurement (see
         <a class="local">
          'When to confirm with TSB'
         </a>
         above). TSB values should be used to decide on whether to initiate phototherapy. However, if the TcB is above the treatment threshold, phototherapy should be initiated while awaiting TSB confirmation. (See
         <a class="medical medical_review" href="/z/d/html/5063.html" rel="external">
          "Unconjugated hyperbilirubinemia in term and late preterm newborns: Initial management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Step 3 – If the newborn's bilirubin level is below the treatment threshold, calculate the difference between the hour-specific TSB threshold for phototherapy and newborn's bilirubin level (
         <a class="calc calc_professional" href="/z/d/html/13421.html" rel="external">
          calculator 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p>
         Decisions regarding timing of follow-up and need for repeat testing are based upon the difference between the hour-specific phototherapy threshold and newborn's bilirubin level (step 3, above), as summarized in the table  (
         <a class="graphic graphic_table graphicRef139498" href="/z/d/graphic/139498.html" rel="external">
          table 1
         </a>
         ) and discussed below. (See
         <a class="local">
          'Determining follow-up and need for additional evaluation and/or treatment'
         </a>
         below and
         <a class="local">
          'Outpatient follow-up'
         </a>
         below.)
        </p>
        <p>
         In general, the smaller the difference, the greater the risk of subsequently developing severe hyperbilirubinemia. A difference of &lt;2 mg/dL (34 micromol/L) warrants close follow-up and possibly treatment. (See
         <a class="local">
          'Approach based upon bilirubin level'
         </a>
         below.)
        </p>
        <p>
         In addition, when two or more bilirubin levels are available, the rate of rise can help identify patients at higher risk of subsequently developing severe hyperbilirubinemia. Rapidly rising bilirubin levels (ie, increasing by ≥0.3 mg/dL [5 micromol/L] per hour in the first 24 hours or ≥0.2 mg/dL [3 micromol/L] per hour thereafter) suggest an underlying hemolytic process. (See
         <a class="local">
          'Testing for hemolysis'
         </a>
         below.)
        </p>
        <p>
         The approach described above is different from previous guidance from the American Academy of Pediatrics (AAP) in which screening and intervention was a two-step process guided by a different hour-specific nomogram that used "risk zones" to categorize the newborn's risk [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         Support for the newer approach comes from a study of nearly 150,000 newborns who underwent bilirubin screening and were discharged from the birth hospitalization, of whom 1.8 percent (2623 newborns) subsequently exceeded the phototherapy threshold [
         <a href="#rid63">
          63
         </a>
         ]. Newborns with predischarge TSB levels ≤1 mg/dL (17 micromol/L) below the phototherapy threshold had a 56 percent probability of subsequently needing treatment, whereas if the difference was &gt;7 mg/dL (120 micromol/L), the probability of subsequently needing treatment was extremely low (0.008 percent). The difference from the phototherapy threshold was more accurate in predicting subsequent need for treatment compared with the older risk zone categorization approach.
        </p>
        <p class="headingAnchor" id="H32013821">
         <span class="h2">
          Risk calculator
         </span>
         <span class="headingEndMark">
          —
         </span>
         The newborn hyperbilirubinemia assessment calculator (
         <a class="calc calc_professional" href="/z/d/html/13421.html" rel="external">
          calculator 1
         </a>
         ) can be used to assess the risk of developing severe hyperbilirubinemia and determine the hour-specific bilirubin threshold for treatment.
        </p>
        <p class="headingAnchor" id="H1184163221">
         <span class="h2">
          Determining follow-up and need for additional evaluation and/or treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         For newborns undergoing bilirubin screening, subsequent evaluation and management during the birth hospitalization must address the following clinical decisions:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Does the newborn require treatment of hyperbilirubinemia and/or escalation of care?
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Is additional evaluation warranted to identify the cause of hyperbilirubinemia (eg, hemolysis)?
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Should the bilirubin level be rechecked and if so, when?
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Can the newborn be discharged, or should they remain in the hospital?
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         When should outpatient follow-up occur?
        </p>
        <p>
        </p>
        <p>
         The following sections provide guidance on these issues. In general, decisions should take into account the following considerations  (
         <a class="graphic graphic_table graphicRef139498" href="/z/d/graphic/139498.html" rel="external">
          table 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         How close the newborn's predischarge total serum or plasma bilirubin (TSB) or transcutaneous bilirubin (TcB) level is to the treatment threshold (
         <a class="calc calc_professional" href="/z/d/html/13421.html" rel="external">
          calculator 1
         </a>
         ). In general, the smaller the difference, the greater the risk of subsequently developing severe hyperbilirubinemia. (See
         <a class="local">
          'Interpretation of bilirubin testing'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Whether there are other risk factors for severe hyperbilirubinemia  (
         <a class="graphic graphic_table graphicRef64584" href="/z/d/graphic/64584.html" rel="external">
          table 3
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The newborn's postnatal and gestational age.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Type of feeding (breastfeeding versus formula) and adequacy of intake.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Family support.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Whether follow-up can be ensured.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Values and preferences of the parents/caregivers.
        </p>
        <p>
        </p>
        <p>
         In general, earlier follow-up is required for newborns born at &lt;38 weeks gestational age (GA) and those with additional risk factors for severe hyperbilirubinemia  (
         <a class="graphic graphic_table graphicRef64584" href="/z/d/graphic/64584.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid1">
          1
         </a>
         ]. TSB levels typically peak between 72 and 96 hours after birth [
         <a href="#rid64">
          64,65
         </a>
         ]. Newborns who are discharged prior to the anticipated peak (ie, before 72 hours) require earlier follow-up to assess for jaundice and decide whether a repeat bilirubin level is needed.
        </p>
        <p>
         Determining the timing for follow-up is particularly challenging when the newborn is discharged just prior to a weekend or a holiday. Under these circumstances, clinicians should use their judgment. As an example, when discharging a formula-fed newborn with a GA of 41 weeks whose TSB level at screening was well below the treatment threshold and without additional risk factors  (
         <a class="graphic graphic_table graphicRef64584" href="/z/d/graphic/64584.html" rel="external">
          table 3
         </a>
         ), it is acceptable to discharge the newborn on a Friday and schedule the follow-up visit on the following Monday or Tuesday. On the other hand, when discharging a newborn with multiple clinical risk factors (eg, predischarge TSB close to the treatment threshold, GA &lt;38 weeks, and exclusively breastfed), the newborn should be seen the following day, regardless of weekends or holidays. If appropriate follow-up cannot be arranged, discharge should be delayed until follow-up can be ensured or the period of greatest risk for hyperbilirubinemia has passed (72 to 96 hours of age).
        </p>
        <p class="headingAnchor" id="H3925363700">
         <span class="h2">
          Approach based upon bilirubin level
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bilirubin near the exchange transfusion threshold
         </strong>
         – Newborns with TSB levels that are approaching or above the threshold for exchange transfusion  (
         <a class="graphic graphic_figure graphicRef68219 graphicRef139429" href="/z/d/graphic/68219.html" rel="external">
          figure 4A-B
         </a>
         )(
         <a class="calc calc_professional" href="/z/d/html/13421.html" rel="external">
          calculator 1
         </a>
         ) require escalation of care, as discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/121592.html" rel="external">
          "Unconjugated hyperbilirubinemia in term and late preterm newborns: Escalation of care"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bilirubin at or above phototherapy threshold
         </strong>
         – For newborns with bilirubin levels at or above the threshold for treatment  (
         <a class="graphic graphic_figure graphicRef56490 graphicRef139427" href="/z/d/graphic/56490.html" rel="external">
          figure 2A-B
         </a>
         )(
         <a class="calc calc_professional" href="/z/d/html/13421.html" rel="external">
          calculator 1
         </a>
         ), phototherapy should be initiated promptly [
         <a href="#rid1">
          1
         </a>
         ]. If screening was performed with TcB, it should be confirmed with a TSB measurement in this setting since decisions regarding phototherapy should be guided by the TSB value not the TcB (see
         <a class="local">
          'When to confirm with TSB'
         </a>
         above). However, phototherapy should be initiated while awaiting TSB confirmation. Details of treatment are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/5063.html" rel="external">
          "Unconjugated hyperbilirubinemia in term and late preterm newborns: Initial management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Additional laboratory evaluation is generally warranted for newborns who require treatment of hyperbilirubinemia during the birth hospitalization, as discussed below. (See
         <a class="local">
          'Additional laboratory evaluation'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bilirubin near phototherapy threshold
         </strong>
         – Newborns with bilirubin levels that are approaching the treatment threshold (ie, &lt;2 mg/dL [34 microL/L] below the phototherapy threshold  (
         <a class="graphic graphic_figure graphicRef56490 graphicRef139427" href="/z/d/graphic/56490.html" rel="external">
          figure 2A-B
         </a>
         )) are at high risk of subsequently needing treatment [
         <a href="#rid1">
          1,63
         </a>
         ]. A TcB value in this range should be confirmed with a TSB measurement. (See
         <a class="local">
          'When to confirm with TSB'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In some cases, it is reasonable to initiate phototherapy early (ie, at near-threshold TSB values rather than waiting for TSB to cross the treatment threshold). Criteria for initiating subthreshold phototherapy are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5063.html" rel="external">
          "Unconjugated hyperbilirubinemia in term and late preterm newborns: Initial management", section on 'Thresholds for treatment'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If phototherapy is not started, the timing of repeat TSB is as follows  (
         <a class="graphic graphic_table graphicRef139498" href="/z/d/graphic/139498.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid1">
          1
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Newborns &lt;24 hours old – For newborns with near-threshold TSB values within the first 24 hours, discharge should be delayed, and TSB should be repeated in four to eight hours. Additional evaluation for hemolytic conditions is warranted if the repeat TSB is rising rapidly, as discussed below. (See
         <a class="local">
          'Testing for hemolysis'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Newborns ≥24 hours old
         <strong>
         </strong>
         – TSB should be repeated in 4 to 12 hours. Decisions regarding discharge are individualized. Options include delaying discharge, discharging with home phototherapy (if the patient meets criteria), or discharging without phototherapy but with close outpatient follow-up. (See
         <a class="local">
          'Outpatient follow-up'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/5063.html" rel="external">
          "Unconjugated hyperbilirubinemia in term and late preterm newborns: Initial management", section on 'Home phototherapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bilirubin moderately below threshold
         </strong>
         – Newborns with bilirubin levels that are between 2 to &lt;7 mg/dL (34 to 120 micromol/L) below the phototherapy threshold  (
         <a class="graphic graphic_figure graphicRef56490 graphicRef139427" href="/z/d/graphic/56490.html" rel="external">
          figure 2A-B
         </a>
         ) are still at risk for subsequently needing treatment and generally warrant follow-up [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         TcB values in this range should be confirmed with TSB if the TcB is &gt;15 mg/dL (257 micromol/L) or within 3 mg/dL (51 micromol/L) of the phototherapy threshold. (See
         <a class="local">
          'When to confirm with TSB'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Most newborns in this category can be discharged home provided follow-up is ensured.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The timing of follow-up and need for repeat bilirubin testing is as follows  (
         <a class="graphic graphic_table graphicRef139498" href="/z/d/graphic/139498.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid1">
          1
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         If the bilirubin is
         <strong>
          2.0 to &lt;3.5 mg/dL (34 to &lt;60 micromol/L)
         </strong>
         below the phototherapy threshold – Recheck bilirubin (with TSB or TcB) in the outpatient setting in 8 to 24 hours. (See
         <a class="local">
          'Outpatient follow-up'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         If the bilirubin is
         <strong>
          3.5 to &lt;5.5 mg/dL (60 to &lt;94 micromol/L)
         </strong>
         below the phototherapy threshold – Recheck with TSB or TcB in the outpatient setting in one to two days. (See
         <a class="local">
          'Outpatient follow-up'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         If the bilirubin is
         <strong>
          5.5 to &lt;7 mg/dL (94 to &lt;120 micromol/L)
         </strong>
         below the phototherapy threshold – Follow-up depends upon the timing of discharge:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For newborns discharged at &lt;72 hours after birth, outpatient follow-up should occur within 48 hours.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Newborns discharged at ≥72 hours after birth can be seen at the initial well-newborn visit within three to five days after discharge, provided no new concerns arise before then. (See
         <a class="medical medical_review" href="/z/d/html/5068.html" rel="external">
          "Overview of the routine management of the healthy newborn infant", section on 'Follow-up visit'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The need for repeat bilirubin testing during the outpatient visit is based upon the clinical assessment at that time (signs of jaundice, feeding adequacy, weight trajectory, parent/caregiver concerns). (See
         <a class="local">
          'Outpatient follow-up'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bilirubin well below threshold
         </strong>
         – Newborns with predischarge bilirubin levels &gt;7 mg/dL (120 micromol/L) below the phototherapy threshold  (
         <a class="graphic graphic_figure graphicRef56490 graphicRef139427" href="/z/d/graphic/56490.html" rel="external">
          figure 2A-B
         </a>
         ) have a low risk of developing severe hyperbilirubinemia [
         <a href="#rid1">
          1,63
         </a>
         ]. Additional testing is generally not required during the birth hospitalization. If the newborn is discharged from the birth hospitalization at ≥72 hours after birth, follow-up specifically related to hyperbilirubinemia is not required unless new concerns arise (eg, feeding difficulties, parent/caregiver concern for jaundice). For newborns discharged at &lt;72 hours, follow-up should occur within two to three days. (See
         <a class="local">
          'Outpatient follow-up'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H305512596">
         <span class="h1">
          ADDITIONAL LABORATORY EVALUATION
         </span>
        </p>
        <p class="headingAnchor" id="H729341896">
         <span class="h2">
          Testing for hemolysis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Additional evaluation for an underlying hemolytic process is warranted if
         <strong>
          any
         </strong>
         of following are present:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Early-onset jaundice (within first 24 hours after birth).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Requirement for phototherapy or exchange transfusion during the birth hospitalization.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rapidly rising TSB levels (ie, increasing by ≥0.3 mg/dL [5 micromol/L] per hour in the first 24 hours or ≥0.2 mg/dL [3 micromol/L] per hour thereafter).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Family history of an inherited hemolytic disorder.
        </p>
        <p>
        </p>
        <p>
         In these circumstances, the following tests should be performed:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Complete blood cell count (CBC), reticulocyte count, and peripheral blood smear
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/5932.html" rel="external">
          "Overview of hemolytic anemias in children", section on 'Laboratory testing'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation for alloimmune hemolytic disease of the newborn
         </strong>
         – This generally includes comparing the newborn's blood type to the mother's and for newborns with incompatible blood types, performing a direct antiglobulin test (DAT, formerly called Coombs). Additional details are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/5933.html" rel="external">
          "Alloimmune hemolytic disease of the newborn: Postnatal diagnosis and management", section on 'Evaluation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation for glucose-6-phosphate dehydrogenase (G6PD) deficiency
         </strong>
         – G6PD testing should be performed if there is clinical concern for hemolysis (ie, any of the findings listed above) but DAT is negative. The prevalence of G6PD deficiency is highest among Kurdish Jews; Black individuals from sub-Saharan Africa or Brazil; African-Americans; and people from Thailand, South China, and India  (
         <a class="graphic graphic_figure graphicRef129472" href="/z/d/graphic/129472.html" rel="external">
          figure 3
         </a>
         ). However, testing for G6PD is warranted even without a suggestive ancestry.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Some laboratories provide qualitative G6PD testing rapidly; however, the results may not accurately identify deficiency. Quantitative testing may take longer to result. Point-of-care testing is now available in some settings [
         <a href="#rid66">
          66
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7111.html" rel="external">
          "Diagnosis and management of glucose-6-phosphate dehydrogenase (G6PD) deficiency", section on 'Confirmatory tests'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7111.html" rel="external">
          "Diagnosis and management of glucose-6-phosphate dehydrogenase (G6PD) deficiency", section on 'Point of care tests under investigation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If there is a high level of clinical concern for G6PD, tests should be ordered urgently. While awaiting results, management and counseling should be provided to the parents/caregivers including avoidance of agents that can trigger hemolysis in the newborn [
         <a href="#rid67">
          67
         </a>
         ]. Parents/caregivers should also be informed at the time of discharge from the birth hospitalization that the newborn is at risk for subsequently having a rapid and dramatic increase in bilirubin level and they should be instructed to seek medical attention is the newborn has an increase in the degree of visible jaundice or other concerning symptoms (eg, poor feeding, lethargy, abnormal cry).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          End-tidal carbon monoxide or carboxyhemoglobin level, corrected for ambient CO (ETCOc or COHbc)
         </strong>
         – If available at the birth center, ETCOc can be a helpful noninvasive tool for confirming active hemolysis in newborns. ETCOc provides a noninvasive assessment of bilirubin production because the breakdown of heme results in the production of equimolar quantities of bilirubin and CO [
         <a href="#rid68">
          68-72
         </a>
         ]. Elevated ETCOc values (&gt;1.7 ppm) can identify newborns with increased bilirubin production due to hemolysis (regardless of etiology) [
         <a href="#rid73">
          73
         </a>
         ]. Commercial ETCOc monitors are available and have been evaluated at a number of institutions as safe and feasible screen for hemolysis [
         <a href="#rid74">
          74-76
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Measurement of COHb, which requires a blood draw, can also help to identify and verify the degree of hemolysis [
         <a href="#rid77">
          77-79
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1424610656">
         <span class="h2">
          Conjugated (direct) hyperbilirubinemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Physiologic hyperbilirubinemia is
         <strong>
          not
         </strong>
         associated with increased conjugated (or direct) bilirubin levels. Conjugated (direct) hyperbilirubinemia is indicative of cholestasis. If the direct bilirubin is &gt;1 mg/dL (17.1 micromol/L), the newborn should undergo evaluation for causes of cholestasis, including biliary atresia, as discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5941.html" rel="external">
          "Approach to evaluation of cholestasis in neonates and young infants"
         </a>
         .)
        </p>
        <p>
         Sepsis is another important cause of conjugated (direct) hyperbilirubinemia. Evaluation for sepsis may be warranted if there are other concerning clinical signs or risk factors for neonatal sepsis. The approach to evaluating for sepsis in newborns is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5043.html" rel="external">
          "Clinical features, evaluation, and diagnosis of sepsis in term and late preterm neonates", section on 'Evaluation and initial management'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h1">
          OUTPATIENT FOLLOW-UP
         </span>
         <span class="headingEndMark">
          —
         </span>
         Appropriate follow-up after discharge is essential, particularly in infants discharged within the first 48 hours after birth, as bilirubin levels have rarely reached their peak levels by this age. (See
         <a class="medical medical_review" href="/z/d/html/5020.html" rel="external">
          "Unconjugated hyperbilirubinemia in neonates: Etiology and pathogenesis", section on 'Peak TSB levels and time to resolution'
         </a>
         .)
        </p>
        <p>
         At the time of discharge, a follow-up appointment is scheduled, the timing of which is determined by the predischarge bilirubin level, other risk factors, and age at discharge, as summarized in the table  (
         <a class="graphic graphic_table graphicRef139498" href="/z/d/graphic/139498.html" rel="external">
          table 1
         </a>
         ) and discussed above. (See
         <a class="local">
          'Determining follow-up and need for additional evaluation and/or treatment'
         </a>
         above.)
        </p>
        <p>
         Documented hand-off should be provided to the newborn's designated healthcare provider. Information and instructions are given to the family on when and whom to contact for medical issues (eg, jaundice and adequacy of feeding) [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="local">
          'Information for patients'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3677824727">
         <span class="h2">
          Follow-up clinical assessment
         </span>
         <span class="headingEndMark">
          —
         </span>
         At the follow-up appointment, the following should be assessed:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Newborn's current weight and percent change from their birth weight. (See
         <a class="medical medical_review" href="/z/d/html/5068.html" rel="external">
          "Overview of the routine management of the healthy newborn infant", section on 'Weight loss'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Adequacy of intake. (See
         <a class="medical medical_review" href="/z/d/html/4986.html" rel="external">
          "Initiation of breastfeeding", section on 'Assessment of intake'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pattern of voiding and transition of stool color.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Visual inspection for cephalocaudal jaundice progression and conjunctival icterus. (See
         <a class="medical medical_review" href="/z/d/html/4994.html" rel="external">
          "Unconjugated hyperbilirubinemia in neonates: Risk factors, clinical manifestations, and neurologic complications", section on 'Jaundice'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2950504025">
         <span class="h2">
          Repeat bilirubin testing
         </span>
        </p>
        <p class="headingAnchor" id="H485205279">
         <span class="h3">
          Whom to test
         </span>
         <span class="headingEndMark">
          —
         </span>
         The need for further bilirubin measurements is based upon the newborn's risk for developing treatment-level hyperbilirubinemia.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Repeat testing based upon predischarge bilirubin level
         </strong>
         – In some cases, the newborn may require repeat testing based upon the results of initial screening performed during the birth hospitalization. The approach to determining the need for follow-up testing in this setting depends upon the predischarge bilirubin level and additional risk factors, as summarized in the table  (
         <a class="graphic graphic_table graphicRef139498" href="/z/d/graphic/139498.html" rel="external">
          table 1
         </a>
         ) and discussed in detail above. (See
         <a class="local">
          'Determining follow-up and need for additional evaluation and/or treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In these cases, the plan for repeating a bilirubin measurement in the outpatient setting should be clearly communicated to the parents/caregivers and outpatient provider. For newborns being discharged when outpatient follow-up is unavailable (eg, during a weekend or holiday), a mechanism should be in place for the newborn to have their bilirubin level checked.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Repeat testing based upon clinical assessment during the first outpatient visit
         </strong>
         – Repeat bilirubin testing may also be warranted based upon the clinical assessment during the outpatient visit. Testing decisions are based chiefly upon:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Whether the newborn appears jaundiced.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Interval medical history (weight change and feeding history).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hyperbilirubinemia risk factors  (
         <a class="graphic graphic_table graphicRef64584" href="/z/d/graphic/64584.html" rel="external">
          table 3
         </a>
         ) – A single clinical risk factor in isolation is generally not sufficient to warrant repeat testing. However, clinicians should have a lower threshold for checking the bilirubin level in newborns with any of these risk factors, particularly if the newborn appears jaundiced.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation of prolonged neonatal jaundice
         </strong>
         – Newborns with prolonged neonatal jaundice should have total and direct bilirubin levels checked. The expected course of neonatal hyperbilirubinemia differs depending on type of feeding (see
         <a class="medical medical_review" href="/z/d/html/5020.html" rel="external">
          "Unconjugated hyperbilirubinemia in neonates: Etiology and pathogenesis", section on 'Peak TSB levels and time to resolution'
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For formula-fed newborns, persistence of jaundice after seven days of age is unusual and warrants evaluation.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For breastfed newborns, jaundice may persist until age 10 to 14 days, or longer. Persistent jaundice beyond age 14 days generally warrants further evaluation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The evaluation and management of unconjugated hyperbilirubinemia that persists or recurs after the newborn is one week old is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/5063.html" rel="external">
          "Unconjugated hyperbilirubinemia in term and late preterm newborns: Initial management", section on 'Prolonged/delayed hyperbilirubinemia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3034362101">
         <span class="h3">
          Test to perform
         </span>
         <span class="headingEndMark">
          —
         </span>
         For newborns who warrant repeat bilirubin measurements, testing may be performed with either total serum bilirubin (TSB) or noninvasively using a transcutaneous bilirubin (TcB) device, if available in the outpatient clinic. When evaluating jaundice in newborns &gt;7 days old, we suggest performing a blood test, including both total and direct bilirubin levels. (See
         <a class="local">
          'Bilirubin testing methods'
         </a>
         above.)
        </p>
        <p>
         Most of the studies supporting use of TcB were performed in the inpatient setting. These data are discussed above. (See
         <a class="local">
          'Transcutaneous bilirubin (TcB)'
         </a>
         above.)
        </p>
        <p>
         There are fewer data on the reliability and accuracy of TcB in the outpatient setting [
         <a href="#rid55">
          55,80-83
         </a>
         ]. In the available reports, TcB values generally correlated with TSB levels (usually within 2 to 3 mg/dL [34 to 51 micromol/L]) [
         <a href="#rid80">
          80-82
         </a>
         ]. The direction of the difference between TcB and TSB values in these studies differed (in some, TcB underestimated TSB; whereas in others, TcB slightly overestimated TSB), reflecting that different TcB devices perform slightly differently from one another. In most studies, a TcB value &lt;13 to 14 mg/dL (222 to 239 micromol/L) reliably identified newborns with TSB values &lt;17 mg/dL (291 micromol/L) [
         <a href="#rid80">
          80,82
         </a>
         ].
        </p>
        <p>
         TcB devices have the same limitations in the outpatient setting as they do in the inpatient setting and the criteria for confirming with TSB are the same, as outlined above. (See
         <a class="local">
          'When to confirm with TSB'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H1218239351">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/116513.html" rel="external">
          "Society guideline links: Neonatal jaundice"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/15455.html" rel="external">
          "Patient education: Jaundice in babies (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/1203.html" rel="external">
          "Patient education: Jaundice in newborn infants (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rational for universal bilirubin screening
         </strong>
         – Hyperbilirubinemia is common and benign in most newborns. Severe hyperbilirubinemia (defined as total serum or plasma bilirubin [TSB] &gt;25 mg/dL [428 micromol/L] in newborns ≥35 weeks gestational age [GA]) may lead to severe permanent neurologic injury if it is not detected and treated promptly. The goals of universal bilirubin screening are to identify newborns at risk for severe hyperbilirubinemia and to provide timely and appropriate preventive therapy. (See
         <a class="local">
          'Benefits of screening'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/4994.html" rel="external">
          "Unconjugated hyperbilirubinemia in neonates: Risk factors, clinical manifestations, and neurologic complications", section on 'Consequences of severe hyperbilirubinemia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Approach to screening
         </strong>
         – For newborn infants ≥35 weeks gestation, we suggest routine predischarge bilirubin screening rather than no screening or selective screening (ie, testing only if the newborn appears jaundiced and/or has risk factors for hyperbilirubinemia) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Observational data suggest that universal screening reduces the incidence of severe hyperbilirubinemia  (
         <a class="graphic graphic_figure graphicRef101082" href="/z/d/graphic/101082.html" rel="external">
          figure 1
         </a>
         ). (See
         <a class="local">
          'Benefits of screening'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Our suggested approach is as follows (see
         <a class="local">
          'Approach to screening'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Testing methods
         </strong>
         – Screening can be performed with either TSB or transcutaneous bilirubin (TcB). (See
         <a class="local">
          'Bilirubin testing methods'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         If screening is performed with TcB, the measurement should be confirmed with TSB if (see
         <a class="local">
          'When to confirm with TSB'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Therapeutic intervention is being considered (phototherapy or exchange transfusion); however, phototherapy can be initiated while awaiting confirmatory TSB results. TcB measurements are
         <strong>
          not
         </strong>
         reliable for newborns undergoing phototherapy and should not be used in this setting.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         TcB is within 3 mg/dL (51 micromol/L) of the phototherapy threshold  (
         <a class="graphic graphic_figure graphicRef56490 graphicRef139427" href="/z/d/graphic/56490.html" rel="external">
          figure 2A-B
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         TcB is &gt;15 mg/dL (257 micromol/L).
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         TcB device displays an "error" message or if there is any question regarding the validity of the TcB measurement.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Timing of screening
         </strong>
         – The timing of the first bilirubin test depends upon whether the newborn is at risk for developing early severe hyperbilirubinemia (see
         <a class="local">
          'Timing of screening'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Early screening – Testing at &lt;24 hours after birth is warranted in newborns who have a positive direct antiglobulin test (DAT), early onset of jaundice (within the first 24 hours after birth), or a first-degree relative with a heritable hemolytic disease (eg, glucose-6 phosphate dehydrogenase [G6PD] deficiency).
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Routine screening – For all other newborns, screening is performed at 24 to 48 hours after birth or before discharge, whichever is sooner. If TSB is used for screening, it is typically performed at the time of the newborn metabolic screen.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Clinical assessment
         </strong>
         – In addition to bilirubin testing, the clinician should assess the newborn for (see
         <a class="local">
          'Clinical assessment'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Risk factors for progressive and/or severe hyperbilirubinemia  (
         <a class="graphic graphic_table graphicRef64584" href="/z/d/graphic/64584.html" rel="external">
          table 3
         </a>
         ) and bilirubin neurotoxicity  (
         <a class="graphic graphic_table graphicRef139425" href="/z/d/graphic/139425.html" rel="external">
          table 2
         </a>
         ) (see
         <a class="local">
          'Risk assessment'
         </a>
         above)
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Visible jaundice and other concerning physical examination findings (see
         <a class="local">
          'Physical examination'
         </a>
         above)
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Adequacy of feeding (see
         <a class="local">
          'Feeding assessment'
         </a>
         above)
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Family history and ancestry (see
         <a class="local">
          'Family history'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Interpretation of bilirubin testing
         </strong>
         – Bilirubin values are interpreted relative to the hour-specific thresholds for treatment, which vary depending upon GA, and other risk factors for bilirubin neurotoxicity  (
         <a class="graphic graphic_table graphicRef139425" href="/z/d/graphic/139425.html" rel="external">
          table 2
         </a>
         and
         <a class="graphic graphic_figure graphicRef56490 graphicRef139427" href="/z/d/graphic/56490.html" rel="external">
          figure 2A-B
         </a>
         ). The approach is summarized in the table  (
         <a class="graphic graphic_table graphicRef139498" href="/z/d/graphic/139498.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Interpretation of bilirubin testing'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Determining follow-up
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Identifying newborns who require treatment
         </strong>
         – Newborns with bilirubin levels at or above the threshold for treatment  (
         <a class="graphic graphic_figure graphicRef56490 graphicRef139427" href="/z/d/graphic/56490.html" rel="external">
          figure 2A-B
         </a>
         and
         <a class="graphic graphic_figure graphicRef68219 graphicRef139429" href="/z/d/graphic/68219.html" rel="external">
          figure 4A-B
         </a>
         )(
         <a class="calc calc_professional" href="/z/d/html/13421.html" rel="external">
          calculator 1
         </a>
         ), should begin treatment, as discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5063.html" rel="external">
          "Unconjugated hyperbilirubinemia in term and late preterm newborns: Initial management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Repeat bilirubin testing and timing of outpatient follow-up
         </strong>
         – For newborns whose screening results are below the treatment threshold, the need for repeat testing and the timing of follow-up are based upon the difference between the phototherapy threshold and the newborn's predischarge TSB level (
         <a class="calc calc_professional" href="/z/d/html/13421.html" rel="external">
          calculator 1
         </a>
         ). The smaller the difference, the greater the risk of subsequently developing severe hyperbilirubinemia. In general, earlier follow-up is required for newborns with risk factors for severe hyperbilirubinemia  (
         <a class="graphic graphic_table graphicRef64584" href="/z/d/graphic/64584.html" rel="external">
          table 3
         </a>
         ) or if discharge occurs before 72 hours. Additional guidance is provided in the table  (
         <a class="graphic graphic_table graphicRef139498" href="/z/d/graphic/139498.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Approach based upon bilirubin level'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Evaluation for hemolysis
         </strong>
         – Hemolysis is suggested by
         <strong>
          any
         </strong>
         of following:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Early-onset jaundice (within first 24 hours after birth)
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Requirement for phototherapy or exchange transfusion during the birth hospitalization
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Rapidly rising TSB levels (ie, increasing by ≥0.3 mg/dL [5 micromol/L] per hour in the first 24 hours or ≥0.2 mg/dL [3 micromol/L] per hour thereafter)
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Family history of an inherited hemolytic disorder
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         If any of these are present, additional testing should include complete blood cell count, reticulocyte count, peripheral blood smear, direct antiglobulin test (DAT), and testing for glucose-6-phosphate dehydrogenase (G6PD) deficiency. If available at the birth center, end-tidal carbon monoxide measurement is a helpful noninvasive tool for confirming hemolysis. (See
         <a class="local">
          'Testing for hemolysis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Outpatient follow-up
         </strong>
         – The follow-up assessment after discharge includes (see
         <a class="local">
          'Follow-up clinical assessment'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Current weight and percent change from birth weight (see
         <a class="medical medical_review" href="/z/d/html/5068.html" rel="external">
          "Overview of the routine management of the healthy newborn infant", section on 'Weight loss'
         </a>
         )
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Assessing adequacy of intake and pattern of voiding and stooling (see
         <a class="medical medical_review" href="/z/d/html/4986.html" rel="external">
          "Initiation of breastfeeding", section on 'Assessment of intake'
         </a>
         )
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Examination for presence/extent of jaundice
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A follow-up bilirubin level should be obtained if the predischarge level warranted repeat testing  (
         <a class="graphic graphic_table graphicRef139498" href="/z/d/graphic/139498.html" rel="external">
          table 1
         </a>
         ), or if concerns arise after discharge (jaundice, feeding difficulties, weight trajectory, parent/caregiver concerns). (See
         <a class="local">
          'Repeat bilirubin testing'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Kemper AR, Newman TB, Slaughter JL, et al. Clinical Practice Guideline Revision: Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation. Pediatrics 2022; 150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guidelines for detection, management and prevention of hyperbilirubinemia in term and late preterm newborn infants (35 or more weeks' gestation) - Summary. Paediatr Child Health 2007; 12:401.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bhutani VK, Johnson L, Sivieri EM. Predictive ability of a predischarge hour-specific serum bilirubin for subsequent significant hyperbilirubinemia in healthy term and near-term newborns. Pediatrics 1999; 103:6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuzniewicz MW, Escobar GJ, Newman TB. Impact of universal bilirubin screening on severe hyperbilirubinemia and phototherapy use. Pediatrics 2009; 124:1031.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mah MP, Clark SL, Akhigbe E, et al. Reduction of severe hyperbilirubinemia after institution of predischarge bilirubin screening. Pediatrics 2010; 125:e1143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Darling EK, Ramsay T, Sprague AE, et al. Universal bilirubin screening and health care utilization. Pediatrics 2014; 134:e1017.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wainer S, Parmar SM, Allegro D, et al. Impact of a transcutaneous bilirubinometry program on resource utilization and severe hyperbilirubinemia. Pediatrics 2012; 129:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eggert LD, Wiedmeier SE, Wilson J, Christensen RD. The effect of instituting a prehospital-discharge newborn bilirubin screening program in an 18-hospital health system. Pediatrics 2006; 117:e855.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Okwundu C, Bhutani VK, Smith J, et al. Predischarge transcutaneous bilirubin screening reduces readmission rate for hyperbilirubinaemia in diverse South African newborns: A randomised controlled trial. S Afr Med J 2020; 110:249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuzniewicz MW, Wickremasinghe AC, Wu YW, et al. Incidence, etiology, and outcomes of hazardous hyperbilirubinemia in newborns. Pediatrics 2014; 134:504.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ebbesen F, Bjerre JV, Vandborg PK. Relation between serum bilirubin levels ≥450 μmol/L and bilirubin encephalopathy; a Danish population-based study. Acta Paediatr 2012; 101:384.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnson L, Bhutani VK, Karp K, et al. Clinical report from the pilot USA Kernicterus Registry (1992 to 2004). J Perinatol 2009; 29 Suppl 1:S25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McClean S, Baerg K, Smith-Fehr J, Szafron M. Cost savings with transcutaneous screening versus total serum bilirubin measurement for newborn jaundice in hospital and community settings: a cost-minimization analysis. CMAJ Open 2018; 6:E285.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xie B, da Silva O, Zaric G. Cost-effectiveness analysis of a system-based approach for managing neonatal jaundice and preventing kernicterus in Ontario. Paediatr Child Health 2012; 17:11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thomas DH, Warner JV, Jones GRD, et al. Total bilirubin assay differences may cause inconsistent treatment decisions in neonatal hyperbilirubinaemia. Clin Chem Lab Med 2022; 60:1736.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lo SF, Doumas BT, Ashwood ER. Performance of bilirubin determinations in US laboratories--revisited. Clin Chem 2004; 50:190.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vreman HJ, Verter J, Oh W, et al. Interlaboratory variability of bilirubin measurements. Clin Chem 1996; 42:869.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuzniewicz MW, Greene DN, Walsh EM, et al. Association Between Laboratory Calibration of a Serum Bilirubin Assay, Neonatal Bilirubin Levels, and Phototherapy Use. JAMA Pediatr 2016; 170:557.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Westenberg LEH, Been JV, Willemsen SP, et al. Diagnostic Accuracy of Portable, Handheld Point-of-Care Tests vs Laboratory-Based Bilirubin Quantification in Neonates: A Systematic Review and Meta-analysis. JAMA Pediatr 2023; 177:479.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grohmann K, Roser M, Rolinski B, et al. Bilirubin measurement for neonates: comparison of 9 frequently used methods. Pediatrics 2006; 117:1174.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barko HA, Jackson GL, Engle WD. Evaluation of a point-of-care direct spectrophotometric method for measurement of total serum bilirubin in term and near-term neonates. J Perinatol 2006; 26:100.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hulzebos CV, Vitek L, Coda Zabetta CD, et al. Screening methods for neonatal hyperbilirubinemia: benefits, limitations, requirements, and novel developments. Pediatr Res 2021; 90:272.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bhutani VK, Gourley GR, Adler S, et al. Noninvasive measurement of total serum bilirubin in a multiracial predischarge newborn population to assess the risk of severe hyperbilirubinemia. Pediatrics 2000; 106:E17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maisels MJ, Kring E. Transcutaneous bilirubinometry decreases the need for serum bilirubin measurements and saves money. Pediatrics 1997; 99:599.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maisels MJ, Kring E. Transcutaneous bilirubin levels in the first 96 hours in a normal newborn population of &gt; or = 35 weeks' gestation. Pediatrics 2006; 117:1169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van den Esker-Jonker B, den Boer L, Pepping RM, Bekhof J. Transcutaneous Bilirubinometry in Jaundiced Neonates: A Randomized Controlled Trial. Pediatrics 2016; 138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Konana OS, Bahr TM, Strike HR, et al. Decision Accuracy and Safety of Transcutaneous Bilirubin Screening at Intermountain Healthcare. J Pediatr 2021; 228:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Slusher TM, Angyo IA, Bode-Thomas F, et al. Transcutaneous bilirubin measurements and serum total bilirubin levels in indigenous African infants. Pediatrics 2004; 113:1636.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fine KL, Carey WA, Schuster JAW, et al. Defining the limitations of transcutaneous bilirubin measurement in late preterm newborns. J Perinatol 2017; 37:658.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taylor JA, Burgos AE, Flaherman V, et al. Discrepancies between transcutaneous and serum bilirubin measurements. Pediatrics 2015; 135:224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Okwundu CI, Saini SS. Noninvasive methods for bilirubin measurements in newborns: A report. Semin Perinatol 2021; 45:151355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ebbesen F, Vandborg PK, Trydal T. Comparison of the transcutaneous bilirubinometers BiliCheck and Minolta JM-103 in preterm neonates. Acta Paediatr 2012; 101:1128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dam-Vervloet AJ, van Erk MD, Doorn N, et al. Inter-device reproducibility of transcutaneous bilirubin meters. Pediatr Res 2021; 89:770.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wainer S, Rabi Y, Parmar SM, et al. Impact of skin tone on the performance of a transcutaneous jaundice meter. Acta Paediatr 2009; 98:1909.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Samiee-Zafarghandy S, Feberova J, Williams K, et al. Influence of skin colour on diagnostic accuracy of the jaundice meter JM 103 in newborns. Arch Dis Child Fetal Neonatal Ed 2014; 99:F480.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olusanya BO, Imosemi DO, Emokpae AA. Differences Between Transcutaneous and Serum Bilirubin Measurements in Black African Neonates. Pediatrics 2016; 138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ho SR, Lin YC, Chen CN. The Impact of Phototherapy on the Accuracy of Transcutaneous Bilirubin Measurements in Neonates: Optimal Measurement Site and Timing. Diagnostics (Basel) 2021; 11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nagar G, Vandermeer B, Campbell S, Kumar M. Effect of Phototherapy on the Reliability of Transcutaneous Bilirubin Devices in Term and Near-Term Infants: A Systematic Review and Meta-Analysis. Neonatology 2016; 109:203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaplan M, Maisels MJ. Natural history of early neonatal bilirubinemia: a global perspective. J Perinatol 2021; 41:873.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Varvarigou A, Fouzas S, Skylogianni E, et al. Transcutaneous bilirubin nomogram for prediction of significant neonatal hyperbilirubinemia. Pediatrics 2009; 124:1052.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Luca D, Romagnoli C, Tiberi E, et al. Skin bilirubin nomogram for the first 96 h of life in a European normal healthy newborn population, obtained with multiwavelength transcutaneous bilirubinometry. Acta Paediatr 2008; 97:146.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fouzas S, Mantagou L, Skylogianni E, et al. Transcutaneous bilirubin levels for the first 120 postnatal hours in healthy neonates. Pediatrics 2010; 125:e52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaplan M, Bromiker R. Variation in Transcutaneous Bilirubin Nomograms across Population Groups. J Pediatr 2019; 208:273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Engle WD, Lai S, Ahmad N, et al. An hour-specific nomogram for transcutaneous bilirubin values in term and late preterm Hispanic neonates. Am J Perinatol 2009; 26:425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanpavat S, Nuchprayoon I, Smathakanee C, Hansuebsai R. Nomogram for prediction of the risk of neonatal hyperbilirubinemia, using transcutaneous bilirubin. J Med Assoc Thai 2005; 88:1187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bental YA, Shiff Y, Dorsht N, et al. Bhutani-based nomograms for the prediction of significant hyperbilirubinaemia using transcutaneous measurements of bilirubin. Acta Paediatr 2009; 98:1902.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yu ZB, Dong XY, Han SP, et al. Transcutaneous bilirubin nomogram for predicting neonatal hyperbilirubinemia in healthy term and late-preterm Chinese infants. Eur J Pediatr 2011; 170:185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Akahira-Azuma M, Yonemoto N, Mori R, et al. An hour-specific transcutaneous bilirubin nomogram for Mongolian neonates. Eur J Pediatr 2015; 174:1299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Han S, Yu Z, Liu L, et al. A Model for Predicting Significant Hyperbilirubinemia in Neonates From China. Pediatrics 2015; 136:e896.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bromiker R, Goldberg A, Kaplan M. Israel transcutaneous bilirubin nomogram predicts significant hyperbilirubinemia. J Perinatol 2017; 37:1315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Engle WD, Jackson GL, Sendelbach D, et al. Assessment of a transcutaneous device in the evaluation of neonatal hyperbilirubinemia in a primarily Hispanic population. Pediatrics 2002; 110:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Luca D, Jackson GL, Tridente A, et al. Transcutaneous bilirubin nomograms: a systematic review of population differences and analysis of bilirubin kinetics. Arch Pediatr Adolesc Med 2009; 163:1054.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taylor JA, Burgos AE, Flaherman V, et al. Utility of Decision Rules for Transcutaneous Bilirubin Measurements. Pediatrics 2016; 137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schumacher RE. Transcutaneous bilirubinometry and diagnostic tests: "the right job for the tool". Pediatrics 2002; 110:407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Engle WD, Jackson GL, Stehel EK, et al. Evaluation of a transcutaneous jaundice meter following hospital discharge in term and near-term neonates. J Perinatol 2005; 25:486.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Casnocha Lucanova L, Matasova K, Zibolen M, Krcho P. Accuracy of transcutaneous bilirubin measurement in newborns after phototherapy. J Perinatol 2016; 36:858.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gothwal S, Singh N, Sitaraman S, et al. Efficacy of transcutaneous bilirubinometry as compared to serum bilirubin in preterm newborn during phototherapy. Eur J Pediatr 2021; 180:2629.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee AC, Folger LV, Rahman M, et al. A Novel Icterometer for Hyperbilirubinemia Screening in Low-Resource Settings. Pediatrics 2019; 143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olusanya BO, Slusher TM, Imosemi DO, Emokpae AA. Maternal detection of neonatal jaundice during birth hospitalization using a novel two-color icterometer. PLoS One 2017; 12:e0183882.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Enweronu-Laryea C, Leung T, Outlaw F, et al. Validating a Sclera-Based Smartphone Application for Screening Jaundiced Newborns in Ghana. Pediatrics 2022; 150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shaw SC, Devgan A. Bilirubin estimation from smartphone imaging of skin of newborns. Acta Paediatr 2020; 109:2822.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aune A, Vartdal G, Bergseng H, et al. Bilirubin estimates from smartphone images of newborn infants' skin correlated highly to serum bilirubin levels. Acta Paediatr 2020; 109:2532.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuzniewicz MW, Park J, Niki H, et al. Predicting the Need for Phototherapy After Discharge. Pediatrics 2021; 147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dennery PA, Seidman DS, Stevenson DK. Neonatal hyperbilirubinemia. N Engl J Med 2001; 344:581.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maisels MJ. What's in a name? Physiologic and pathologic jaundice: the conundrum of defining normal bilirubin levels in the newborn. Pediatrics 2006; 118:805.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wong RJ, Montiel C, Kunda M, et al. A novel point-of-care device for measuring glucose-6-phosphate dehydrogenase enzyme deficiency. Semin Perinatol 2021; 45:151356.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaplan M, Hammerman C, Bhutani VK. Parental education and the WHO neonatal G-6-PD screening program: a quarter century later. J Perinatol 2015; 35:779.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stevenson DK, Fanaroff AA, Maisels MJ, et al. Prediction of hyperbilirubinemia in near-term and term infants. Pediatrics 2001; 108:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stevenson DK, Vreman HJ. Carbon monoxide and bilirubin production in neonates. Pediatrics 1997; 100:252.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bartoletti AL, Stevenson DK, Ostrander CR, Johnson JD. Pulmonary excretion of carbon monoxide in the human infant as an index of bilirubin production. I. Effects of gestational and postnatal age and some common neonatal abnormalities. J Pediatr 1979; 94:952.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vreman HJ, Stevenson DK, Oh W, et al. Semiportable electrochemical instrument for determining carbon monoxide in breath. Clin Chem 1994; 40:1927.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stevenson DK, Vreman HJ, Oh W, et al. Bilirubin production in healthy term infants as measured by carbon monoxide in breath. Clin Chem 1994; 40:1934.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bhutani VK, Srinivas S, Castillo Cuadrado ME, et al. Identification of neonatal haemolysis: an approach to predischarge management of neonatal hyperbilirubinemia. Acta Paediatr 2016; 105:e189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castillo Cuadrado ME, Bhutani VK, Aby JL, et al. Evaluation of a new end-tidal carbon monoxide monitor from the bench to the bedside. Acta Paediatr 2015; 104:e279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Christensen RD, Lambert DK, Henry E, et al. End-tidal carbon monoxide as an indicator of the hemolytic rate. Blood Cells Mol Dis 2015; 54:292.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bahr TM, Shakib JH, Stipelman CH, et al. Improvement Initiative: End-Tidal Carbon Monoxide Measurement in Newborns Receiving Phototherapy. J Pediatr 2021; 238:168.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaplan M, Hammerman C, Vreman HJ, et al. Hemolysis and hyperbilirubinemia in antiglobulin positive, direct ABO blood group heterospecific neonates. J Pediatr 2010; 157:772.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schutzman DL, Gatien E, Ajayi S, Wong RJ. Carboxyhemoglobin levels as a predictor of risk for significant hyperbilirubinemia in African-American DAT(+) infants. J Perinatol 2016; 36:386.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaplan M, Hammerman C, Vreman HJ, et al. Direct antiglobulin titer strength and hyperbilirubinemia. Pediatrics 2014; 134:e1340.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maisels MJ, Engle WD, Wainer S, et al. Transcutaneous bilirubin levels in an outpatient and office population. J Perinatol 2011; 31:621.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wickremasinghe AC, Karon BS, Cook WJ. Accuracy of neonatal transcutaneous bilirubin measurement in the outpatient setting. Clin Pediatr (Phila) 2011; 50:1144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ercan Ş, Özgün G. The accuracy of transcutaneous bilirubinometer measurements to identify the hyperbilirubinemia in outpatient newborn population. Clin Biochem 2018; 55:69.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kumra T, Weaver SJ, Prather K, et al. Correlation of Transcutaneous and Serum Bilirubin Measurements in the Outpatient Setting. Clin Pediatr (Phila) 2018; 57:231.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 5008 Version 78.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35927462" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Clinical Practice Guideline Revision: Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19030400" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Guidelines for detection, management and prevention of hyperbilirubinemia in term and late preterm newborn infants (35 or more weeks' gestation) - Summary.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9917432" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Predictive ability of a predischarge hour-specific serum bilirubin for subsequent significant hyperbilirubinemia in healthy term and near-term newborns.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19786442" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Impact of universal bilirubin screening on severe hyperbilirubinemia and phototherapy use.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20368324" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Reduction of severe hyperbilirubinemia after institution of predischarge bilirubin screening.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25246625" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Universal bilirubin screening and health care utilization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22184646" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Impact of a transcutaneous bilirubinometry program on resource utilization and severe hyperbilirubinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16651290" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : The effect of instituting a prehospital-discharge newborn bilirubin screening program in an 18-hospital health system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32657704" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Predischarge transcutaneous bilirubin screening reduces readmission rate for hyperbilirubinaemia in diverse South African newborns: A randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25092943" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Incidence, etiology, and outcomes of hazardous hyperbilirubinemia in newborns.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22176133" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Relation between serum bilirubin levels≥450μmol/L and bilirubin encephalopathy; a Danish population-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19177057" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Clinical report from the pilot USA Kernicterus Registry (1992 to 2004).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30054296" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Cost savings with transcutaneous screening versus total serum bilirubin measurement for newborn jaundice in hospital and community settings: a cost-minimization analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23277747" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Cost-effectiveness analysis of a system-based approach for managing neonatal jaundice and preventing kernicterus in Ontario.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36036565" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Total bilirubin assay differences may cause inconsistent treatment decisions in neonatal hyperbilirubinaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14633931" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Performance of bilirubin determinations in US laboratories--revisited.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8665677" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Interlaboratory variability of bilirubin measurements.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27064480" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Association Between Laboratory Calibration of a Serum Bilirubin Assay, Neonatal Bilirubin Levels, and Phototherapy Use.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36912856" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Diagnostic Accuracy of Portable, Handheld Point-of-Care Tests vs Laboratory-Based Bilirubin Quantification in Neonates: A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16585313" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Bilirubin measurement for neonates: comparison of 9 frequently used methods.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16407962" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Evaluation of a point-of-care direct spectrophotometric method for measurement of total serum bilirubin in term and near-term neonates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33941863" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Screening methods for neonatal hyperbilirubinemia: benefits, limitations, requirements, and novel developments.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10920173" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Noninvasive measurement of total serum bilirubin in a multiracial predischarge newborn population to assess the risk of severe hyperbilirubinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9093305" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Transcutaneous bilirubinometry decreases the need for serum bilirubin measurements and saves money.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16585312" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Transcutaneous bilirubin levels in the first 96 hours in a normal newborn population of&gt;or = 35 weeks' gestation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27940715" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Transcutaneous Bilirubinometry in Jaundiced Neonates: A Randomized Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32890579" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Decision Accuracy and Safety of Transcutaneous Bilirubin Screening at Intermountain Healthcare.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15173484" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Transcutaneous bilirubin measurements and serum total bilirubin levels in indigenous African infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28206994" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Defining the limitations of transcutaneous bilirubin measurement in late preterm newborns.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25601981" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Discrepancies between transcutaneous and serum bilirubin measurements.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33317823" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Noninvasive methods for bilirubin measurements in newborns: A report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22931293" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Comparison of the transcutaneous bilirubinometers BiliCheck and Minolta JM-103 in preterm neonates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32919392" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Inter-device reproducibility of transcutaneous bilirubin meters.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19764923" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Impact of skin tone on the performance of a transcutaneous jaundice meter.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25074981" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Influence of skin colour on diagnostic accuracy of the jaundice meter JM 103 in newborns.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27577578" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Differences Between Transcutaneous and Serum Bilirubin Measurements in Black African Neonates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34574069" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : The Impact of Phototherapy on the Accuracy of Transcutaneous Bilirubin Measurements in Neonates: Optimal Measurement Site and Timing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26789390" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Effect of Phototherapy on the Reliability of Transcutaneous Bilirubin Devices in Term and Near-Term Infants: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33398058" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Natural history of early neonatal bilirubinemia: a global perspective.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19786443" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Transcutaneous bilirubin nomogram for prediction of significant neonatal hyperbilirubinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18254903" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Skin bilirubin nomogram for the first 96 h of life in a European normal healthy newborn population, obtained with multiwavelength transcutaneous bilirubinometry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20008429" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Transcutaneous bilirubin levels for the first 120 postnatal hours in healthy neonates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30853197" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Variation in Transcutaneous Bilirubin Nomograms across Population Groups.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19263335" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : An hour-specific nomogram for transcutaneous bilirubin values in term and late preterm Hispanic neonates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16536103" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Nomogram for prediction of the risk of neonatal hyperbilirubinemia, using transcutaneous bilirubin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19508300" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Bhutani-based nomograms for the prediction of significant hyperbilirubinaemia using transcutaneous measurements of bilirubin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20814696" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Transcutaneous bilirubin nomogram for predicting neonatal hyperbilirubinemia in healthy term and late-preterm Chinese infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25869495" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : An hour-specific transcutaneous bilirubin nomogram for Mongolian neonates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26391945" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : A Model for Predicting Significant Hyperbilirubinemia in Neonates From China.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29192695" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Israel transcutaneous bilirubin nomogram predicts significant hyperbilirubinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12093947" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Assessment of a transcutaneous device in the evaluation of neonatal hyperbilirubinemia in a primarily Hispanic population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19884597" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Transcutaneous bilirubin nomograms: a systematic review of population differences and analysis of bilirubin kinetics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27244792" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Utility of Decision Rules for Transcutaneous Bilirubin Measurements.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12165601" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Transcutaneous bilirubinometry and diagnostic tests: "the right job for the tool".
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15908989" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Evaluation of a transcutaneous jaundice meter following hospital discharge in term and near-term neonates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27279078" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Accuracy of transcutaneous bilirubin measurement in newborns after phototherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34120212" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Efficacy of transcutaneous bilirubinometry as compared to serum bilirubin in preterm newborn during phototherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30952779" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : A Novel Icterometer for Hyperbilirubinemia Screening in Low-Resource Settings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28837635" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Maternal detection of neonatal jaundice during birth hospitalization using a novel two-color icterometer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35656782" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Validating a Sclera-Based Smartphone Application for Screening Jaundiced Newborns in Ghana.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32506603" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Bilirubin estimation from smartphone imaging of skin of newborns.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32267569" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Bilirubin estimates from smartphone images of newborn infants' skin correlated highly to serum bilirubin levels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33903163" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Predicting the Need for Phototherapy After Discharge.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11207355" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Neonatal hyperbilirubinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16882840" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : What's in a name? Physiologic and pathologic jaundice: the conundrum of defining normal bilirubin levels in the newborn.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33293060" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : A novel point-of-care device for measuring glucose-6-phosphate dehydrogenase enzyme deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26181718" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Parental education and the WHO neonatal G-6-PD screening program: a quarter century later.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11433051" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Prediction of hyperbilirubinemia in near-term and term infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9240808" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Carbon monoxide and bilirubin production in neonates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/448544" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Pulmonary excretion of carbon monoxide in the human infant as an index of bilirubin production. I. Effects of gestational and postnatal age and some common neonatal abnormalities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7923774" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Semiportable electrochemical instrument for determining carbon monoxide in breath.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7923775" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Bilirubin production in healthy term infants as measured by carbon monoxide in breath.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26802319" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Identification of neonatal haemolysis: an approach to predischarge management of neonatal hyperbilirubinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25640053" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Evaluation of a new end-tidal carbon monoxide monitor from the bench to the bedside.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25624169" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : End-tidal carbon monoxide as an indicator of the hemolytic rate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34260896" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Improvement Initiative: End-Tidal Carbon Monoxide Measurement in Newborns Receiving Phototherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20598320" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Hemolysis and hyperbilirubinemia in antiglobulin positive, direct ABO blood group heterospecific neonates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26765551" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Carboxyhemoglobin levels as a predictor of risk for significant hyperbilirubinemia in African-American DAT(+) infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25332496" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Direct antiglobulin titer strength and hyperbilirubinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21293381" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Transcutaneous bilirubin levels in an outpatient and office population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22013149" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Accuracy of neonatal transcutaneous bilirubin measurement in the outpatient setting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29601801" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : The accuracy of transcutaneous bilirubinometer measurements to identify the hyperbilirubinemia in outpatient newborn population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28952368" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Correlation of Transcutaneous and Serum Bilirubin Measurements in the Outpatient Setting.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
